Evaluation of the effect of glorenta in diabetes

Evaluation of the effect of glorenta (ampagliflozin + linagliptin) on the reduction of Fbs (Fast blood sugar) and Hba1c (Hemoglobin A1C) in type 2 diabetics resistant to other oral therapies

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210524051383N1

Enrollment

Registered

2021-07-22

Start date

2021-07-11

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients. Diabetes mellitus due to underlying condition

Interventions

Intervention group: Type 2 diabetic patients resistant to other oral anti-diabetic therapies. These patients receive Glorenta coated tablets made by Abidi Company (a combination of two blood sugar con

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: No history of kidney disease Informed consent

Exclusion criteria

Exclusion criteria: Patients with clinical evidence of renal failure Urinary tract infection (UTI) Allergy to empagliflozin or lina gliptin including urticaria and intolerable eczema Respiratory infection Diarrhea Cough Increase blood urea nitrogen (BUN)

Design outcomes

Primary

Measure	Time frame
Hemoglobin A1C (HbA1c). Timepoint: Before the start of the study and 3 months later. Method of measurement: Blood test.;Fbs (Fast blood sugar). Timepoint: Before the start of the study and 3 months later. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Rasoul Mirtalebi

Shahre-kord University of Medical Sciences

st-mirtalebi.r@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026